相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。HIV-HCV co-infected patients with low CD4+cell nadirs are at risk for faster fibrosis progression and portal hypertension
T. Reiberger et al.
JOURNAL OF VIRAL HEPATITIS (2010)
Public Health Impact of Antiviral Therapy for Hepatitis C in the United States
Michael L. Volk et al.
HEPATOLOGY (2009)
Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India
Syed S. Hissar et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Forewarned is forearmed
Stefan Zeuzem
JOURNAL OF HEPATOLOGY (2009)
HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C
Stella De Nicola et al.
JOURNAL OF HEPATOLOGY (2009)
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C
Pierre-Yves Bochud et al.
JOURNAL OF HEPATOLOGY (2009)
The impact of hepatic steatosis on the natural history of chronic hepatitis C infection
T. J. S. Cross et al.
JOURNAL OF VIRAL HEPATITIS (2009)
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Christophe Hezode et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
PLOS MEDICINE (2009)
Disease progression in chronic hepatitis C: Modifiable and nonmodifiable factors
Sharif B. Missiha et al.
GASTROENTEROLOGY (2008)
The cyclophilin inhibitor debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus
Robert Flisiak et al.
HEPATOLOGY (2008)
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression
Hla-Hla Thein et al.
HEPATOLOGY (2008)
Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count
P. Bonnard et al.
JOURNAL OF VIRAL HEPATITIS (2007)
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
Mitchell L. Shiffman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection
P Perumalswami et al.
HEPATOLOGY (2006)
Natural history and predictors of disease severity in chronic hepatitis C
J Massard et al.
JOURNAL OF HEPATOLOGY (2006)
Epidemiology of viral hepatitis and HIV co-infection
MJ Alter
JOURNAL OF HEPATOLOGY (2006)
A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C
MM Richardson et al.
JOURNAL OF MEDICAL GENETICS (2005)
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C
C Hézode et al.
HEPATOLOGY (2005)
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C
L Fartoux et al.
GUT (2005)
Rate of natural disease progression in patients with chronic hepatitis C
JP Zarski et al.
JOURNAL OF HEPATOLOGY (2003)
Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus
C Martinez-Sierra et al.
CLINICAL INFECTIOUS DISEASES (2003)
Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies
L Castéra et al.
GUT (2003)
Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection
J Westin et al.
JOURNAL OF VIRAL HEPATITIS (2002)
Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-β
S Kanzler et al.
JOURNAL OF VIRAL HEPATITIS (2001)
Medical progress: Hepatitis C virus infection.
GM Lauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
LE Adinolfi et al.
HEPATOLOGY (2001)